Valuation: PREDILIFE

Market Cap 3.35M 3.76M 3.11M 2.83M 5.34M 358M 5.43M 37.43M 14.64M 186M 14.12M 13.82M 595M P/E 2024
-3.18x
P/E 2025 -3.01x
Enterprise Value 8.13M 9.12M 7.54M 6.87M 12.94M 867M 13.17M 90.73M 35.49M 452M 34.22M 33.5M 1.44B EV / Sales 2024
34.5x
EV / Sales 2025 19.3x
Free-Float
48.75%
Yield 2024 *
-
Yield 2025 -
1 day-5.56%
1 week-6.59%
Current month-15.84%
1 month-16.67%
3 months-52.91%
6 months-72.93%
Current year-71.76%
1 week 0.85
Extreme 0.85
0.9
1 month 0.85
Extreme 0.85
1.02
Current year 0.85
Extreme 0.85
4
1 year 0.85
Extreme 0.85
4
3 years 0.85
Extreme 0.85
24
5 years 0.85
Extreme 0.85
24
10 years 0.85
Extreme 0.85
24
Manager TitleAgeSince
Chief Executive Officer 56 2003-12-31
Chief Tech/Sci/R&D Officer - 2006-12-31
General Counsel - 2015-12-31
Director TitleAgeSince
Chairman 56 2003-12-31
Director/Board Member 46 2017-12-31
Director/Board Member 58 2017-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
7/27/23 Buy

Chief Executive Officer

1,200 0.0328%
3/23/22 Sell

Chief Executive Officer

3,000 0.0820%
3/9/22 Buy

Chief Executive Officer

2,000 0.0546%
Change 5-day change 1-year change 3-year change Capi.($)
-5.56%-6.59%-74.01%-85.22% 3.95M
+0.21%-7.67%+61.07%+71.32% 68.92B
+1.66%-9.54%+10.39%+60.04% 51.9B
+3.14%+4.61%+15.36%+44.42% 48.73B
+3.45%+5.01%+32.37%+35.96% 43.13B
-2.20%-5.78%+298.44%+532.76% 41.48B
+6.43%+2.76%+16.56%+109.23% 39.96B
+1.28%-0.76%+12.67%+45.10% 30.6B
-2.21%-14.22%+40.33%-0.94% 26.01B
+1.74%-5.30%-12.09%-12.92% 22.27B
Average +0.79%-3.62%+40.11%+79.98% 37.3B
Weighted average by Cap. +1.58%-3.49%+56.57%+105.30%

Financials

2024 2025
Net sales 493K 553K 458K 417K 785K 52.58M 799K 5.5M 2.15M 27.39M 2.08M 2.03M 87.43M 836K 937K 775K 706K 1.33M 89.1M 1.35M 9.33M 3.65M 46.41M 3.52M 3.44M 148M
Net income -4.26M -4.78M -3.96M -3.6M -6.79M -455M -6.91M -47.58M -18.61M -237M -17.95M -17.57M -756M -3.93M -4.41M -3.65M -3.32M -6.26M -419M -6.37M -43.9M -17.17M -218M -16.56M -16.21M -697M
Net Debt 3.54M 3.97M 3.28M 2.99M 5.63M 377M 5.73M 39.48M 15.44M 196M 14.89M 14.58M 627M 4.78M 5.36M 4.43M 4.04M 7.6M 509M 7.74M 53.31M 20.85M 265M 20.11M 19.68M 847M
Projected Income Statement - Annual - PREDILIFE
Logo PREDILIFE
PREDILIFE specializes in the development of predictive tests, particularly in the field of oncology. The company has MammoRisk®, a breast cancer predictive test that uses a first mammogram and a few questions to obtain a first risk assessment. A genetic test then makes it possible to estimate the risk of breast cancer more accurately. The technology used by MammoRisk® makes it possible to evaluate, from a database of individuals monitored over time, the risks of an individual compared to the future of his « closest » neighbours thanks to a database of over 1,000,000 American women, and over 300,000 French women. PREDILIFE also develops multi-pathology tests to screen for colon, prostate and lung cancer, melanoma and cardiovascular risks.
Employees
21
Date Price Change Volume
26-10-15 €0.8500 -5.56% 2
26-10-14 €0.9000 +1.12% 900
26-10-13 €0.8900 0.00% 0
26-10-12 €0.8900 0.00% 165
26-10-09 €0.8900 -2.20% 384

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - PREDILIFE
  1. Stock Market
  2. Stocks
  3. ALPRE Stock